利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

448 条记录 (耗时 0.032 秒)

    T-CELL VACCINATION WITH VIRAL VECTORS VIA MECHANICAL EPIDERMAL DISRUPTION
    92.
    发明申请
    T-CELL VACCINATION WITH VIRAL VECTORS VIA MECHANICAL EPIDERMAL DISRUPTION 审中-公开
    通过机械性静脉破坏的病毒载体的T细胞疫苗接种

    公开(公告)号：WO2012151272A2

    公开(公告)日：2012-11-08

    申请号：PCT/US2012/036114

    申请日：2012-05-02

    申请人： TREMRX, INC. ,  KUPPER, Thomas, S. ,  LIU, Luzheng ,  CLARK, Rachael, A.

    发明人： KUPPER, Thomas, S. ,  LIU, Luzheng ,  CLARK, Rachael, A.

    IPC分类号： A61K39/02

    CPC分类号： A61K39/0011 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/54 ,  A61K2039/541 ,  C12N2710/24134 ,  C12N2710/24143 ,  Y02A50/386 ,  Y02A50/394 ,  Y02A50/403 ,  Y02A50/41 ,  Y02A50/412 ,  Y02A50/478 ,  Y02A50/484

    摘要： Attenuated, replication-deficient viruses such as vaccinia viruses are used to deliver an exogenous viral, bacterial, parastic or tumor antigen to an epidermal tissue such as the skin, lungs or gastrointestinal tract, which has been mechanically disrupted, in an amount effective to elicit or stimulate a cell mediated immune response. The epidermal tissue may be mechanically disrupted by a device such as a scarification needle or an abrader device. The epidermis may be mechanically disrupted prior to, at the same time, or immediately after the administration of the vaccine. The vaccine can be used to induce immunity against a pathogen, such as a virus, bacteria, or parasite, or against a cancer in a subject that has or is at risk of developing cancer. In some embodiments a co- stimulatory molecule, a growth factor, an adjuvant and/or a cytokine is administered before, with or after the viral vaccine. In some embodiments, the co-stimulatory molecule is co-expressed with the antigen by the virus.

    摘要翻译： 减毒的复制缺陷型病毒如痘苗病毒用于将外源性病毒，细菌，碎片或肿瘤抗原递送至已被机械破坏的表皮组织如皮肤，肺或胃肠道，其数量有效引出 或刺激细胞介导的免疫应答。 表皮组织可能被诸如刮痕针或磨擦装置之类的装置机械地破坏。 在施用疫苗之前，同时或之后，表皮可能被机械破坏。 该疫苗可以用于诱导针对病原体（例如病毒，细菌或寄生虫）或具有发生癌症风险的受试者中的癌症的免疫。 在一些实施方案中，在病毒疫苗之前，之中或之后施用共刺激分子，生长因子，佐剂和/或细胞因子。 在一些实施方案中，共刺激分子与病毒与抗原共表达。

    THIOLACTONE ANTIBIOTICS
    93.
    发明申请
    THIOLACTONE ANTIBIOTICS 审中-公开
    噻吗酮抗生素

    公开(公告)号：WO2012135027A2

    公开(公告)日：2012-10-04

    申请号：PCT/US2012/030354

    申请日：2012-03-23

    申请人： THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK ,  TONGE, Peter ,  MACHUTTA, Carl ,  BOMMINENI, Gopal, Reddy ,  KAPILASHRAMI, Kanishk

    发明人： TONGE, Peter ,  MACHUTTA, Carl ,  BOMMINENI, Gopal, Reddy ,  KAPILASHRAMI, Kanishk

    IPC分类号： C07D333/32 ,  C07D409/06 ,  C07D409/12 ,  A61K31/381 ,  A61P31/00

    CPC分类号： C07D333/32 ,  A61K31/381 ,  C07D409/06 ,  C07D409/12 ,  Y02A50/478 ,  Y02A50/479

    摘要： This invention provides a compound having the structure (I) wherein R 1 is H, (II) or (III), wherein n and q are independently an integer from 0 to 8; A is absent or present and when present is (IV), (V), (VI), (VII), (VIII), or (IX), wherein m is an integer from 0 to 8; R 3 is an amino, alkyl, aryl, heteroaryl, diol, piperazine, morpholine, piperidine, triazole, azide or biphenyl, each with or without substitution, branched or unbranched, or (X); and R 4 is alkyl, aryl, or heteroaryl, each with or without substitution, branched or unbranched, R 2 is H, CH 3 , or alkyl, aryl, heteroaryl, pyrrole, diazole, or triazole, each with or without substitution, branched or unbranched, or (XI), wherein n and q are independently an integer from 0 to 8; A is absent or present and when present is (IV), (V), (VI), (VII), or (VIII); and R 6 is azide, methoxy, trifluoromethyl, biphenyl, substituted phenyl, substituted triazole, or alkyl, aryl or heteroaryl, with or without substitution, branched or unbranched, when R 1 is H then R 2 is other than H or CH 3 , and when R 2 is H or CH 3 then R 1 is other than H, or a pharmaceutically acceptable salt thereof.

    摘要翻译： 本发明提供具有式（I）的化合物，其中R 1为H，（II）或（III），其中n和q独立地为0至8的整数; （IV），（V），（VI），（VII），（VIII）或（IX）所示的化合物，其中m为0至8的整数; 或者（X）; R 3是具有或不具有取代基，支链或非支链的氨基，烷基，芳基，杂芳基，二醇，哌嗪，吗啉，哌啶，三唑，叠氮化物或联苯。 R 4是烷基，芳基或杂芳基，各自具有或不具有取代，支链或非支链，R2是H，CH3或烷基，芳基，杂芳基，吡咯，二唑或三唑，各自具有或不具有取代，支链或非支链， 或（XI），其中n和q独立地为0至8的整数; （IV），（V），（VI），（VII）或（VIII）存在的情况; 并且当R 1为H时，R 6为叠氮基，甲氧基，三氟甲基，联苯基，取代的苯基，取代的三唑或烷基，芳基或杂芳基，具有或不具有取代，分支或未分支，则R2不是H或CH3， H或CH 3，然后R 1不是H，或其药学上可接受的盐。